Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting

BACKGROUND: Inhibitors of dipeptidyl-peptidase IV are recommended as second-line therapy in type 2 diabetes (DT2), but data, as a first-line treatment in everyday clinical practice are scarce. To address this issue we conducted a 12-month, clinical study in an outpatient setting, using vildagliptin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yavropoulou, M. P., Pikilidou, M., Kotsa, K., Michopoulos, A., Papakonstantinou, E., Yovos, J. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563902/
https://www.ncbi.nlm.nih.gov/pubmed/26355765
http://dx.doi.org/10.1186/s40200-015-0194-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563902/
https://www.ncbi.nlm.nih.gov/pubmed/26355765
http://dx.doi.org/10.1186/s40200-015-0194-6

Ejemplares similares